Researchers at Penn State have developed novel contrast agents that target two proteins implicated in osteoarthritis, a degenerative joint disease. By marking the proteins with the contrast agents, which comprise newly designed metal nanoprobes, the researchers can use advanced imaging, called photon-counting computed tomography, to simultaneously track separate biological processes in color, which, together, reveal more about the disease’s progression than a traditional scan. “This high-resolution … imaging approach could potentially be used to image multiple biological targets, thus enabling disease progression tracking over time,” said Dipanjan Pan, one of the scientists involved in this study. Read additional details about the research here: https://www.psu.edu/news/research/story/new-technique-allows-technicolor-imaging-degenerative-joint-disease.
An official website of the United States government.
